Updated time: 2024-05-27 14:48:58
28A-1100423
2021-05-19
RU 2816182、USP pending
Mono-GlcNAc decorated spike protein vaccine provides better protection against infections of SARS-CoV-2 and its variants of concern, such as B.1.1.7 (UK), B.1.351 (SouthAfrica) and P.1 (Brazil). Although many COVID-19 vaccines are available as of 2021, SARS-CoV-2 variants of concern continue to be a major problem due to their ability to escape from the protection of the current available vaccines, and possibility of reinfection. Spike protein, which is the main immunogen in all current vaccines, is heavily glycosylated and the epitopes covered by glycans
are usually less immunogenic. Mono-GlcNAc decorated spike protein vaccine, when vaccinated, can elicit better immune response with a more complete protection against all possible epitopes from spike polypeptide sequence, and provide better protection against infections from variants of concerns.
Compared to currently available COVID-19 vaccines, including mRNA, adenovirus, inactivated virus and recombinant protein, the mono-GlcNAc decorated spike protein vaccine elicits better protection against infections of SARS-CoV-2 and its variants of concern.
Vaccination of monoglycosylated spike vaccine elicits better protection against infections of SARS-CoV-2 and its variants of concern.
Che Ma, Chi-Huey Wong.
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Mono-GlcNAc decorated spike vaccine for SARS-CoV-2 and its variants of concern